Day One Biopharmaceuticals (DAWN) Operating Margin: 2024-2025
Historic Operating Margin for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to -60.94%.
- Day One Biopharmaceuticals' Operating Margin fell 9255.00% to -60.94% in Q3 2025 from the same period last year, while for Sep 2025 it was -123.90%, marking a year-over-year change of. This contributed to the annual value of -165.65% for FY2024, which is N/A change from last year.
- According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Operating Margin is -60.94%, which was up 40.92% from -103.14% recorded in Q2 2025.
- In the past 5 years, Day One Biopharmaceuticals' Operating Margin registered a high of 31.61% during Q3 2024, and its lowest value of -1,401.45% during Q2 2024.
- Its 2-year average for Operating Margin is -315.19%, with a median of -118.32% in 2025.
- Over the last 5 years, Day One Biopharmaceuticals' Operating Margin had its largest YoY gain of 129,831bps in 2025, and its largest YoY loss of 9,255bps in 2025.
- Over the past 2 years, Day One Biopharmaceuticals' Operating Margin (Quarterly) stood at -223.68% in 2024, then tumbled by 9,255bps to -60.94% in 2025.
- Its Operating Margin was -60.94% in Q3 2025, compared to -103.14% in Q2 2025 and -133.50% in Q1 2025.